Selkirk Pharma Welcomes Colleen Dixon as Chief Executive Officer

• Selkirk Pharma has appointed Colleen Dixon as its new CEO, succeeding founder Patrick Haffey.

• Dixon brings over 30 years of industry experience, including senior roles at AstraZeneca, Baxter Biopharma Solutions, and Eli Lilly.

Selkirk Pharma Inc., a U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, has named Colleen Dixon as its new Chief Executive Officer. Dixon steps into the role previously held by Patrick Haffey, the company’s founder and Chairman, who has led Selkirk Pharma for the past six years.

Dixon, who was previously the Vice President of Program Management at Selkirk Pharma, brings extensive experience in biopharmaceutical R&D, manufacturing, and leadership. Her career spans over 30 years with significant roles at AstraZeneca, Baxter Biopharma Solutions, and Eli Lilly and Company.

“It is my distinct pleasure to welcome Colleen Dixon as the new Chief Executive Officer of Selkirk Pharma,” said Jim Bell, Chairman of the Board for Selkirk Pharma. “With Colleen’s exceptional leadership skills, extensive industry experience, and visionary approach, we are confident that she will steer our company towards growth and success.”

In her new role, Dixon will focus on scaling operations, forming key industry partnerships, and driving the company’s growth. She expressed enthusiasm about the future, highlighting Selkirk Pharma’s state-of-the-art facility and dedicated team. “As we bring more capacity online to ensure a reliable supply of medications to patients, I am excited to drive our growth, foster innovation, and establish strong alliances that will benefit our stakeholders and customers in the aseptic fill/finish industry,” Dixon stated.